Sotagliflozin found to protect kidney and heart in patients with type 2 diabetes and chronic kidney disease

November 3 2023

Credit: Pixabay/CC0 Public Domain
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are medications that lower blood sugar levels among other effects, provide kidney- and heart-related benefits to patients with and without diabetes. An exploratory analysis recently uncovered the effects of sotagliflozin, a dual SGLT1 and 2 inhibitor, in patients with type 2 diabetes and chronic kidney disease. The research will be presented at ASN Kidney Week 2023 November 1–5.

The analysis involved data from the SCORED trial, a phase 3, double-blind, placebo-controlled study that randomized 10,584 patients with type 2 diabetes, chronic kidney disease, and cardiovascular factors to receive sotagliflozin or placebo. The outcomes assessed included kidney and cardiorenal composites derived using laboratory values.

Over a median follow-up of 16 months, 223 events were identified, and sotagliflozin reduced the risk of the composite of sustained ≥50% decline in estimated glomerular filtration rate, estimated glomerular filtration rate.

Citation: Sotagliflozin found to protect kidney and heart in patients with type 2 diabetes and chronic kidney disease (2023, November 3) retrieved 7 June 2024 from https://medicalxpress.com/news/2023-11-sotagliflozin-kidney-heart-patients-diabetes.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.